

MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy
Jan 26, 2023
Experts Aaron Gerds and Lucia Masarova discuss key updates in myeloproliferative neoplasms (MPNs) presented at ASH 2022, including the MOMENTUM trial, combination approaches, and novel agents like calreticulin-targeting antibodies. They also explore advancements in fibrosis treatment, the role of immunotherapies in eliminating malignant clones, and challenges in MPN treatment for accelerated and blast phase diseases.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Choosing Between Combination Therapy and Novel Jack Inhibitors in Myelofibrosis: balancing side effects and positive results
02:56 • 2min
Advancements and Future Prospects in Fibrosis Treatment
05:24 • 5min
Targeting the Malignant Clone and the Role of Immunotherapies
09:57 • 3min
Updates and Challenges in MPN Treatment
12:43 • 2min